KissPeptin-10vsTestagen

KissPeptin-10 is the shortest bioactive fragment of the kisspeptin family, derived from the 145-amino-acid precursor protein encoded by the KISS1 gene. The kisspeptin system was identified as the master upstream regulator of the hypothalamic-pituitary-gonadal (HPG) axis when loss-of-function mutations in its receptor (KISS1R/GPR54) were found to cause hypogonadotropic hypogonadism — complete failure of puberty and reproductive function.

Kisspeptin-10 binds to KISS1R (formerly GPR54), a Gq/11-coupled GPCR expressed predominantly on GnRH neurons in the hypothalamus, specifically in two key nuclei: the arcuate nucleus (ARC) and the anteroventral periventricular nucleus (AVPV). KISS1R activation stimulates phospholipase C, generating IP3 and DAG, which raise intracellular calcium and activate protein kinase C in GnRH neurons. This depolarizes the neurons and triggers GnRH release into the hypophyseal portal system, which then stimulates FSH and LH secretion from anterior pituitary gonadotrophs.

What makes kisspeptin extraordinary is its position at the very apex of the reproductive hormone cascade. It sits upstream of GnRH itself, integrating metabolic, circadian, and hormonal signals to determine when and how strongly GnRH pulses fire. Kisspeptin neurons in the ARC co-express neurokinin B and dynorphin (forming the 'KNDy' neuron population) and function as the GnRH pulse generator — the fundamental oscillator that drives pulsatile reproductive hormone secretion. Estradiol and testosterone feed back to kisspeptin neurons (not directly to GnRH neurons) to regulate the HPG axis, making kisspeptin the integration point for sex steroid feedback. This upstream position makes kisspeptin-10 a uniquely powerful tool for stimulating the entire reproductive axis from the top, with clinical potential for triggering ovulation in IVF protocols and restoring fertility in functional hypogonadism.

Testagen is a short Khavinson tetrapeptide (Lys-Glu-Asp-Gly) positioned as the male reproductive and prostate tissue bioregulator within the wider Khavinson peptide family. The proposed mechanism is consistent with the family-wide model: short peptides interact with gene promoter regions in target tissue cells, modulating tissue-specific gene expression patterns to support normal cellular function and counteract age-related decline.

Proposed targets include genes regulating prostate epithelial proliferation and differentiation, androgen receptor signalling sensitivity, and local immune function within prostatic and testicular tissue. Russian research groups have reported testagen-induced improvements in indices of urinary and sexual function in elderly men with age-related prostatic and testicular decline, and animal studies have suggested effects on testicular function markers and prostate gland histology.

As with all Khavinson bioregulators, the published efficacy evidence sits almost entirely within Russian gerontology research traditions and has not been replicated in independent Western randomised controlled trials. Importantly, testagen is not validated for the prevention or treatment of prostate cancer or benign prostatic hyperplasia, and its safety in men with hormone-sensitive cancers has not been established. Use should not displace evidence-based urology care, and users with prostate concerns should consult a urologist rather than relying on bioregulator protocols.